. Author manuscript; available in PMC: 2019 Sep 5.

Published in final edited form as: J Autism Dev Disord. 2017 Jun;47(6):1749–1755. doi: 10.1007/s10803-017-3097-1

Table 1:

Description of Studies Contributing Data to the Main Analysis.

Study	Sample Size		Age Range	Study Description	pQCT	DXA
Study	No-ASD	ASD	Age Range	Study Description	4% Site	LS	TBLH
Study 1	103	18	7 to 17 years	Cross-sectional observational study in participants who had received risperidone for at least six months to examine the skeletal effects of risperidone	X	X	---
Study 2	4	2	10 to 18 years	Cross-sectional observational study in participants who had received risperidone for at least one year to examine the skeletal effects of antipsychotics	X	X	---
Study 3	45	10	5 to 17 years	Randomized placebo-controlled trial of calcium and vitamin D supplementation in participants who had received risperidone for at least one year and exhibited hyperprolactinemia (only baseline data used in this analysis)	X	---	X
Study 4	4	0	5 to 16 years	Longitudinal observational study of largely antipsychotic-naïve participants to examine the effect of risperidone on the gut microbiota. Six participants initiated treatment with risperidone within the prior month (only baseline data used in this analysis)	---	---	X

pQCT: Peripheral quantitative computed tomography. DXA: Dual-energy x-ray absorptiometry.

LS: Lumbar spine. TBLH: Total body less head.